Four Facts on Why Importing Drugs is Bad for Patients

How Successful Negotiation Takes Place in Medicare

Protecting Beneficiaries Who Receive Extra Help

Why Medicaid-Style Rebates Aren’t Good for Part D Beneficiaries or the Program

Fact Check Friday: The Truth About Negotiation in Medicare Part D

Chart Pack: Value of Personalized Medicine

PhRMA Statement on Senator Warren’s Proposal

01.22.15 | By

Developing innovative, lifesaving medicines for patients is the sole focus of the biopharmaceutical industry. PhRMA member companies invested more than $50 billion in research and development (R&D) in 2013 and over half a trillion dollars since 2000. This represents the vast majority of all biopharmaceutical R&D spending – both private and government – in the United States.

Recognizing the Value of Innovation in HIV/AIDS Therapy

A new white paper from Boston Healthcare Associates takes a closer look at the remarkable advances we’ve made in the treatment of HIV/AIDS. Progress against HIV/AIDS has occurred through a series of incremental gains in knowledge and discovery, transforming what was once considered an acute fatal illness into a manageable chronic condition for those who have access to treatment.

PhRMA Reporter's Handbook 2014

Debunking the Myths of Treating Hepatitis C

11.04.14 | By

A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)


Subscribe to RSS - Value